

CMS Manual System

Pub 100-04 Medicare Claims Processing

Transmittal 756

Department of Health &
Human Services (DHHS)

Center for Medicare &
Medicaid Services (CMS)

Date: NOVEMBER 10, 2005

Change Request 4142

SUBJECT: Temporary Hook and Hold of OPPS Claims that Include Certain HCPCS with Status Indicator of G or K

I. SUMMARY OF CHANGES: A standard system program must be created to “hook” and hold claims with bill types 12x, 13x,14x, or 76x or 13x with condition code 41, with dates of service on or after January 1, 2006, where one or more of the HCPCS codes with status indicator G or K, from the attached list, is included.

NEW/REVISED MATERIAL

EFFECTIVE DATE: January 01, 2006

IMPLEMENTATION DATE: January 03, 2006

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated)

R = REVISED, N = NEW, D = DELETED – *Only One Per Row.*

R/N/D	Chapter / Section / SubSection / Title
-------	--

III. FUNDING:

No additional funding will be provided by CMS; Contractor activities are to be carried out within their FY 2006 operating budgets.

IV. ATTACHMENTS:

One-Time Notification

**Unless otherwise specified, the effective date is the date of service.*

Attachment – One-Time Notification

Pub. 100-04	Transmittal: 756	Date: November 10, 2005	Change Request 4142
-------------	------------------	-------------------------	---------------------

SUBJECT: Temporary Hook and Hold of OPPS Claims that Include Certain HCPCS with Status Indicator of G or K

I. GENERAL INFORMATION

A. Background: CMS has proposed to pay for all outpatient drugs using ASP pricing. The schedule for submission of all ASP pricing is statutory per Section 621(a) of the MMA. Drug manufacturers are required to submit drug ASPs within 30 days of the close of their fiscal quarter. Given the complexity, volume of data, and the number of drugs effected, approximately 6 weeks are required to process, validate, and issue final ASPs for a given quarter. The ASP rates for drugs furnished on or after January 1, 2006, won't be available until mid-December, 2005.

The 2006 OPPS Pricer is ready for implementation on January 1, 2006. However, the drug HCPCS, which are included in the attached list, won't have the new drug prices included, for the reasons explained above. All submitted claims after January 1, 2006, should be processed and paid except for those claims that include one or more listed HCPCS codes (with status indicator G or K) on the attached list of drugs. These claims will need to be held until a revised Pricer, that includes the new drug payment information, can be finalized, validated and tested. We expect to have the revised Pricer available as soon as possible after January 1, 2006.

B. Policy: A standard system program must be created to “hook” and hold claims with bill types 12x, 13x, 14x, or 76x or 13x with condition code 41, with dates of service on or after January 1, 2006, where one or more of the HCPCS codes with status indicator G or K, from the attached list, is included. Those claims can be processed to payment when the revised OPPS Pricer software has become effective in production.

II. BUSINESS REQUIREMENTS

"Shall" denotes a mandatory requirement

"Should" denotes an optional requirement

Requirement Number	Requirements	Responsibility (“X” indicates the columns that apply)								
		F I	R H I	C a r r i e r	D M E R C	Shared System Maintainers				Other
						F I S S	M C S	V M S	C W F	

Requirement Number	Requirements	Responsibility (“X” indicates the columns that apply)								
		F I	R H I	C a r r i e r	D M E R C	Shared System Maintainers				Other
						F I S S	M C S	V M S	C W F	
4142.1	The standards system maintainer shall create a program to form a “hook” to hold claims with bill types 12x, 13x, 14x, or 76 x or 13x with condition code 41, with dates of services on or after 1/1/2006, that include HCPCS codes from the attached list with status indicator G or K.					X				
4142.2	The fiscal intermediary shall process “hooked” claims to payment after the revised Pricer software has become effective in production	X								

III. PROVIDER EDUCATION

Requirement Number	Requirements	Responsibility (“X” indicates the columns that apply)								
		F I	R H I	C a r r i e r	D M E R C	Shared System Maintainers				Other
						F I S S	M C S	V M S	C W F	
4142.3	No provider education is required for this instruction.	X								

IV. SUPPORTING INFORMATION AND POSSIBLE DESIGN CONSIDERATIONS

A. Other Instructions: N/A

X-Ref Requirement #	Instructions

B. Design Considerations: N/A

X-Ref Requirement #	Recommendation for Medicare System Requirements

C. Interfaces: N\A

D. Contractor Financial Reporting/Workload Impact: N\A

E. Dependencies: N\A

F. Testing Considerations: N\A

V. SCHEDULE, CONTACTS, AND FUNDING

Effective Date*: January 1, 2006 Implementation Date: January 3, 2006 Pre-Implementation Contact(s): Chuck Braver, (410) 786-6719 Post-Implementation Contact(s): Appropriate Regional Office	No additional funding will be provided by CMS; contractor activities are to be carried out within their FY 2006 operating budgets.
--	---

***Unless otherwise specified, the effective date is the date of service.**

Attachment

2006 HCPCS	Description	2006 SI	2006 APC
C9220	Sodium hyaluronate	G	9220
C9221	Graftjacket Reg Matrix	G	9221
C9222	Graftjacket SftTis	G	9222
C9225	Fluocinolone acetonide	G	9225
J0128	Abarelix, Inject Suspension	G	9216
J0878	Injection, daptomycin	G	9124
J2278	Ziconotide injection	G	1694
J2357	Injection, Omalizumab	G	9300
J2503	Pegaptanib sodium injection	G	1697
J2783	Rasburicase	G	0738
J2794	Injection, risperidone	G	9125
J7518	Mycophenolic Acid, Oral	G	9219
J8501	Oral aprepitant	G	0868
J9027	Clofarabine injection	G	1710
J9035	Injection, Bevacizumab	G	9214
J9055	Injection, Cetuximab	G	9215
J9264	Paclitaxel injection	G	1712
J9305	Injection, Pemetrexed	G	9213
Q4079	Injection, natalizumab	G	9126
C1178	BUSULFAN IV, 6 Mg	K	1178
C9003	Palivizumab, per 50 mg	K	9003
C9121	Injection, argatroban	K	9121
J0130	Abciximab injection	K	1605
J0135	Adalimumab injection	K	1083
J0150	Injection adenosine 6 MG	K	0379
J0152	Adenosine injection	K	0917
J0180	Injection, agalsidase beta	K	9208
J0205	Alglucerase injection	K	0900
J0207	Amifostine	K	7000
J0210	Methyldopate hcl injection	K	2210
J0256	Alpha 1 proteinase inhibitor	K	0901
J0285	Amphotericin B	K	9030
J0287	Amphotericin b lipid complex	K	9024
J0288	Ampho b cholesteryl sulfate	K	0735
J0289	Amphotericin b liposome inj	K	0736
J0395	Arbutamine HCl injection	K	9031
J0475	Baclofen 10 MG injection	K	9032
J0475	Baclofen 10 MG injection	K	9032
J0585	Botulinum toxin a per unit	K	0902
J0587	Botulinum toxin type B	K	9018
J0600	Edetate calcium disodium inj	K	0892
J0630	Calcitonin salmon injection	K	0893
J0637	Caspofungin acetate	K	9019
J0706	Caffeine citrate injection	K	0876
J0735	Clonidine hydrochloride	K	0935
J0740	Cidofovir injection	K	9033
J0800	Corticotropin injection	K	1280
J0835	Inj cosyntropin per 0.25 MG	K	0835
J0850	Cytomegalovirus imm IV /vial	K	0903
J0895	Deferoxamine mesylate inj	K	0895

2006 HCPCS	Description	2006 SI	2006 APC
J1110	Inj dihydroergotamine mesylt	K	1210
J1190	Dexrazoxane HCl injection	K	0726
J1260	Dolasetron mesylate	K	0750
J1327	Eptifibatide injection	K	1607
J1330	Ergonovine maleate injection	K	1330
J1410	Inj estrogen conjugate 25 MG	K	9038
J1436	Etidronate disodium inj	K	1436
J1438	Etanercept injection	K	1608
J1440	Filgrastim 300 mcg injection	K	0728
J1441	Filgrastim 480 mcg injection	K	7049
J1452	Intraocular Fomivirsen na	K	9040
J1457	Gallium nitrate injection	K	1085
J1565	RSV-ivig	K	0906
J1566	Immune globulin, powder	K	2731
J1567	Immune globulin, liquid	K	2732
J1610	Glucagon hydrochloride/1 MG	K	9042
J1620	Gonadorelin hydroch/ 100 mcg	K	7005
J1626	Granisetron HCl injection	K	0764
J1655	Tinzaparin sodium injection	K	1655
J1670	Tetanus immune globulin inj	K	1670
J1730	Diazoxide injection	K	1740
J1742	Ibutilide fumarate injection	K	9044
J1745	Infliximab injection	K	7043
J1756	Iron sucrose injection	K	9046
J1785	Injection imiglucerase /unit	K	0916
J1830	Interferon beta-1b / .25 MG	K	0910
J1835	Itraconazole injection	K	9047
J1931	Injection, laronidase	K	9209
J1950	Leuprolide acetate /3.75 MG	K	0800
J2020	Linezolid injection	K	9001
J2353	Octreotide injection, depot	K	1207
J2355	Oprelvekin injection	K	7011
J2405	Ondansetron hcl injection	K	0768
J2425	Palifermin injection	K	1696
J2430	Pamidronate disodium /30 MG	K	0730
J2469	Injection, palonosetron HCL	K	9210
J2505	Injection, pegfilgrastim 6mg	K	9119
J2700	Oxacillin sodium injeciton	K	1635
J2730	Pralidoxime chloride inj	K	2730
J2770	Quinupristin/dalfopristin	K	2770
J2788	Rho d immune globulin 50 mcg	K	9023
J2790	Rho d immune globulin inj	K	0884
J2792	Rho(D) immune globulin h, sd	K	1609
J2820	Sargramostim injection	K	0731
J2940	Somatrem injection	K	2940
J2941	Somatropin injection	K	7034
J2993	Reteplase injection	K	9005
J2995	Inj streptokinase /250000 IU	K	0911
J2997	Alteplase recombinant	K	7048
J3030	Sumatriptan succinate / 6 MG	K	3030

2006 HCPCS	Description	2006 SI	2006 APC
J3100	Tenecteplase injection	K	9002
J3240	Thyrotropin injection	K	9108
J3246	Tirofiban hydrochloride	K	7041
J3305	Inj trimetrexate glucuronate	K	7045
J3315	Triptorelin pamoate	K	9122
J3350	Urea injection	K	9051
J3365	Urokinase 250,000 IU inj	K	7036
J3396	Verteporfin injection	K	1203
J3465	Injection, voriconazole	K	1052
J3487	Zoledronic acid	K	9115
J7190	Factor viii	K	0925
J7191	Factor VIII (porcine)	K	0926
J7192	Factor viii recombinant	K	0927
J7193	Factor IX non-recombinant	K	0931
J7194	Factor ix complex	K	0928
J7195	Factor IX recombinant	K	0932
J7198	Anti-inhibitor	K	0929
J7308	Aminolevulinic acid hcl top	K	7308
J7310	Ganciclovir long act implant	K	0913
J7342	Metabolically active tissue	K	9054
J7344	Nonmetabolic active tissue	K	9156
J7350	Injectable human tissue	K	9055
J7501	Azathioprine parenteral	K	0887
J7502	Cyclosporine oral 100 mg	K	0888
J7504	Lymphocyte immune globulin	K	0890
J7505	Monoclonal antibodies	K	7038
J7507	Tacrolimus oral per 1 MG	K	0891
J7511	Antithymocyte globuln rabbit	K	9104
J7513	Daclizumab, parenteral	K	1612
J7515	Cyclosporine oral 25 mg	K	7515
J7517	Mycophenolate mofetil oral	K	9015
J7520	Sirolimus, oral	K	9020
J7525	Tacrolimus injection	K	9006
J8510	Oral busulfan	K	7015
J8520	Capecitabine, oral, 150 mg	K	7042
J8560	Etoposide oral 50 MG	K	0802
J8700	Temozolomide	K	1086
J9001	Doxorubicin hcl liposome inj	K	7046
J9010	Alemtuzumab injection	K	9110
J9015	Aldesleukin/single use vial	K	0807
J9017	Arsenic trioxide	K	9012
J9020	Asparaginase injection	K	0814
J9031	Bcg live intravesical vac	K	0809
J9040	Bleomycin sulfate injection	K	0857
J9041	Injection, bortezomib	K	9207
J9045	Carboplatin injection	K	0811
J9050	Carmus bischl nitro inj	K	0812
J9065	Inj cladribine per 1 MG	K	0858
J9098	Cytarabine liposome	K	1166
J9130	Dacarbazine 100 mg inj	K	0819

2006 HCPCS	Description	2006 SI	2006 APC
J9150	Daunorubicin	K	0820
J9151	Daunorubicin citrate liposom	K	0821
J9160	Denileukin diftitox, 300 mcg	K	1084
J9170	Docetaxel	K	0823
J9178	Inj, epirubicin hcl, 2 mg	K	1167
J9185	Fludarabine phosphate inj	K	0842
J9200	Floxuridine injection	K	0827
J9201	Gemcitabine HCl	K	0828
J9202	Goserelin acetate implant	K	0810
J9206	Irinotecan injection	K	0830
J9208	Ifosfomide injection	K	0831
J9209	Mesna injection	K	0732
J9211	Idarubicin hcl injection	K	0832
J9212	Interferon alfacon-1	K	0912
J9213	Interferon alfa-2a inj	K	0834
J9214	Interferon alfa-2b inj	K	0836
J9215	Interferon alfa-n3 inj	K	0865
J9216	Interferon gamma 1-b inj	K	0838
J9217	Leuprolide acetate suspnsion	K	9217
J9218	Leuprolide acetate injecton	K	0861
J9219	Leuprolide acetate implant	K	7051
J9245	Inj melphalan hydrochl 50 MG	K	0840
J9265	Paclitaxel injection	K	0863
J9266	Pegaspargase/singl dose vial	K	0843
J9268	Pentostatin injection	K	0844
J9270	Plicamycin (mithramycin) inj	K	0860
J9280	Mitomycin 5 MG inj	K	0862
J9293	Mitoxantrone hydrochl / 5 MG	K	0864
J9300	Gemtuzumab ozogamicin	K	9004
J9310	Rituximab cancer treatment	K	0849
J9320	Streptozocin injection	K	0850
J9340	Thiotepa injection	K	0851
J9350	Topotecan	K	0852
J9355	Trastuzumab	K	1613
J9390	Vinorelbine tartrate/10 mg	K	0855
J9395	Injection, Fulvestrant	K	9120
J9600	Porfimer sodium	K	0856
P9041	Albumin (human),5%, 50ml	K	0961
P9045	Albumin (human), 5%, 250 ml	K	0963
P9046	Albumin (human), 25%, 20 ml	K	0964
P9047	Albumin (human), 25%, 50ml	K	0965
Q0166	Granisetron HCl 1 mg oral	K	0765
Q0179	Ondansetron HCl 8mg oral	K	0769
Q0180	Dolasetron mesylate oral	K	0763
Q2009	Fosphenytoin, 50 mg	K	7028
Q2017	Teniposide, 50 mg	K	7035
Q3025	IM inj interferon beta 1-a	K	9022
Q9945	LOCM <=149 mg/ml iodine, 1ml	K	9157

2006 HCPCS	Description	2006 SI	2006 APC
Q9946	LOCM 150-199mg/ml iodine,1ml	K	9158
Q9947	LOCM 200-249mg/ml iodine,1ml	K	9159
Q9948	LOCM 250-299mg/ml iodine,1ml	K	9160
Q9949	LOCM 300-349mg/ml iodine,1ml	K	9161
Q9950	LOCM 350-399mg/ml iodine,1ml	K	9162
Q9951	LOCM >= 400 mg/ml iodine,1ml	K	9163
Q9952	Inj Gad-base MR contrast, ml	K	9164
Q9954	Oral MR contrast, 100 ml	K	9165
Q9955	Perflexane lipid micro	K	9203
Q9956	Octafluoropropane	K	9202
Q9957	Perflutren lipid micro, 2ml	K	9112
90371	Hep b ig, im	K	1630
90375	Rabies ig, im/sc	K	9133
90376	Rabies ig, heat treated	K	9134
90396	Varicella-zoster ig, im	K	9135
90476	Adenovirus vaccine, type 4	K	9136
90581	Anthrax vaccine, sc	K	9169
90585	Bcg vaccine, percut	K	9137
90636	Hep a/hep b vacc, adult im	K	9138
90665	Lyme disease vaccine, im	K	9170
90675	Rabies vaccine, im	K	9139
90676	Rabies vaccine, id	K	9140
90708	Measles-rubella vaccine, sc	K	9141
90714	Td vaccine no prsrv >= 7 im	K	1634
90716	Chicken pox vaccine, sc	K	9142
90717	Yellow fever vaccine, sc	K	1636
90733	Meningococcal vaccine, sc	K	9143
90734	Meningococcal vaccine, im	K	9145
90735	Encephalitis vaccine, sc	K	9144
A9535	Injection, methylene blue	K	1640
C9224	Injection, galsulfase	K	9224
J0132	Acetylcysteine injection	K	1680
J0215	Alefacept	K	1633
J0215	Alefacept	K	1633
J0278	Amikacin sulfate injection	K	1681
J0350	Injection anistreplase 30 u	K	1606
J0365	Aprotonin, 10,000 kiu	K	1682
J0470	Dimecaprol injection	K	1638
J0476	Baclofen intrathecal trial	K	1631
J0480	Basiliximab	K	1683
J0795	Corticotropin ovine triflutal	K	1684
J0881	Darbepoetin alfa, non-esrd	K	1685

2006 HCPCS	Description	2006 SI	2006 APC
J0885	Epoetin alfa, non-esrd	K	1686
J1162	Digoxin immune fab (ovine)	K	1687
J1180	Dyphylline injection	K	9166
J1430	Ethanolamine oleate	K	1688
J1451	Fomepizole	K	1689
J1640	Hemin	K	1690
J1751	Iron dextran 165 injection	K	1691
J1752	Iron dextran 267 injection	K	1692
J1945	Lepiridin	K	1693
J2325	Nesiritide injection	K	1695
J2504	Pegademase bovine, 25 iu	K	1739
J2513	Pentastarch 10% solution	K	1698
J2805	Sincalide injection	K	1699
J2850	Inj secretin synthetic human	K	1700
J2910	Aurothioglucose injeciton	K	1639
J3285	Treprostinil injection	K	1701
J3355	Urofollitropin, 75 iu	K	1741
J3470	Hyaluronidase injection	K	1637
J3471	Ovine, up to 999 USP units	K	1702
J3472	Ovine, 1000 USP units	K	1703
J7188	Inj Vonwillebrand factor iu	K	1704
J7189	Factor viia	K	1705
J7197	Antithrombin iii injection	K	0930
J7318	Hyaluron/deriv intra-art inj	K	1706
J7340	Metabolic active D/E tissue	K	1632
J7340	Metabolic active D/E tissue	K	1632
J7341	Non-human, metabolic tissue	K	1707
J7343	Nonmetabolic act d/e tissue	K	1629
J8540	Oral dexamethasone	K	1708
J9025	Azacitidine injection	K	1709
J9225	Histrelin implant	K	1711
J9263	Oxaliplatin	K	1738
J9357	Valrubicin, 200 mg	K	9167
Q9953	Inj Fe-based MR contrast, ml	K	1713
Q9958	HOCM <=149 mg/ml iodine	K	1714
Q9960	HOCM 200-249mg/ml iodine	K	1715
Q9961	HOCM 250-299mg/ml iodine	K	1734
Q9962	HOCM 300-349mg/ml iodine	K	1735
Q9963	HOCM 350-399mg/ml iodine	K	1736
Q9964	HOCM >= 400 mg/ml iodine	K	1737